Thierry André, MD, on Pembrolizumab vs Chemotherapy in MSI-High Colorectal Cancer
2021 ASCO Annual Meeting
Thierry André, MD, of Hôpital Saint-Antoine, discusses final overall survival data for the phase III KEYNOTE-177 study, which confirmed pembrolizumab as a new standard of care for first-line treatment of patients with microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer (Abstract 3500).
The ASCO Post Staff
Martin Reck, MD, PhD, of LungenClinic, discusses a 2-year update of the CheckMate 9LA study, which sought to determine whether nivolumab plus ipilimumab combined with two cycles of chemotherapy is more effective than four cycles of chemotherapy alone as a first-line treatment for patients with stage IV non–small cell lung cancer (Abstract 9000).
The ASCO Post Staff
Brian I. Rini, MD, of Vanderbilt University, discusses findings from KEYNOTE-426, the longest follow-up of a checkpoint inhibitor (pembrolizumab) combined with a VEGF/VEGFR inhibitor (axitinib) for first-line clear cell renal cell carcinoma. The trial results continue to support this combination as a standard of care for patients with previously untreated disease (Abstract 4500).
The ASCO Post Staff
Nadia Harbeck, MD, PhD, of Ludwig Maximilian University of Munich, discusses results from the ADAPT HR–/HER2+ trial, which showed, for the first time, improved pathologic complete response and survival in patients with early breast cancer who were treated weekly with a de-escalated 12-week regimen of neoadjuvant paclitaxel plus pertuzumab and trastuzumab (Abstract 503).
The ASCO Post Staff
Neeraj Agarwal, MD, of Huntsman Cancer Institute at the University of Utah, discusses phase III data from the SWOG S1216 trial, which evaluated the clinical benefit of using androgen-deprivation therapy with either orteronel (or TAK-700, a CYP17 inhibitor) or bicalutamide in patients with newly diagnosed metastatic hormone-sensitive prostate cancer (Abstract 5001).
The ASCO Post Staff
Bijal D. Shah, MD, of the H. Lee Moffitt Cancer Center, discusses phase II results of the ZUMA-3 study, which evaluated brexucabtagene autoleucel (KTE-X19), an anti-CD19 CAR T-cell therapy, in adults with relapsed or refractory B-cell acute lymphoblastic leukemia (Abstract 7002).